ClinicalTrials.gg
CompletedNCT06194864Updated Sep 19, 2024

Drug Interaction Study

A Phase 1 interventional study of Itraconazole and rifampicin in Drug Interaction, sponsored by Emalex Biosciences Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Emalex Biosciences Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (Part 1) or rifampicin (Part 2) in healthy subjects.

02

Conditions studied

  • Drug Interaction
03

In context

Lead sponsor

Emalex Biosciences Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects or femail subjects of non-
  • ≥18 and ≤55 years of age
  • >18.5 and \<30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
  • Subjects must be healthy, as determined by the Investigator, based on medical history, physical examination, , vital signs, and standard panel of blood and laboratory tests at Screening.
  • Sexually active males must use a double barrier method of during the study and for at least 90 days after the last dose of study drug.
  • Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
  • Willing to take off dentures or mouth piercing at the time of dosing.

Exclusion criteria

Exclusion Criteria:

  • History of significant medical illness
  • abnormalities on screening tests/exams
  • History of or significant risk of committing suicide
  • Donation of plasma within 7 days prior to dosing
  • Donation or significant loss of blood within 8 weeks prior to the first dosing
  • Major surgery within 3 months or minor surgery within 1 month prior to admission
  • Use of prohibited prescription, over-the-counter medications or natural health products
  • Female subjects who are currently pregnant or lactating
  • Positive pregnancy test
  • Positive urine drug screen, urine cotinine test, or alcohol breath test
  • Use of tobacco or nicotine products within 1 month prior to Screening
  • Significant alcohol consumption
  • History of drug abuse within the previous year, or a positive drug screen
  • History of allergy to study medications
  • Part 1 only: Presence of orthodontic braces or orthodontic retention wires
  • Recent participation in a clinical research study
  • Not suitable for study in the opinion of the Principal Investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Part 1

    ecopipam 89.6 mg on Days 1 and 9 with repeat doses of itraconazole Days 6-16.

    Drug: Itraconazole · Drug: Ecopipam

  • Experimental
    Part 2

    ecopipam 179.2 mg on Days 1 and 13 with repeat doses of rifampicin days 6-20.

    Drug: rifampicin · Drug: Ecopipam

Interventions

  • itraconazole 200 mg QD Days 6 to 16

  • rifampicin 600 mg QD Days 6 to 20

  • 89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2

06

What researchers measure

Primary outcomes

  1. AUC0-inf of ecopipam when administered with itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  2. AUC0-inf of ecopipam when administered without itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  3. AUC0-inf of ecopipam when administered with rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  4. AUC0-inf of ecopipam when administered without rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  5. AUC0-t of ecopipam when administered with itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  6. AUC0-t of ecopipam when administered without itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  7. AUC0-t of ecopipam when administered with rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  8. AUC0-t of ecopipam when administered without rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  9. Cmax of ecopipam when administered with itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  10. Cmax of ecopipam when administered without itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  11. Cmax of ecopipam when administered with rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  12. Cmax of ecopipam when administered without rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  13. T½ el of ecopipam when administered with itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  14. T½ el of ecopipam when administered without itraconazole

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  15. T½ el of ecopipam when administered with rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  16. T½ el of ecopipam when administered without rifampicin

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

Secondary outcomes

  1. AUC0-inf of EBS-101-40853

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  2. AUC0-inf of ecopipam glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  3. AUC0-inf of EBS-101-40853 glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  4. AUC0-t of EBS-101-40853

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  5. AUC0-t of ecopipam glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  6. AUC0-t of EBS-101-40853 glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  7. Cmax of EBS-101-40853

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  8. Cmax of ecopipam glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  9. Cmax of EBS-101-40853 glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  10. T½ el of EBS-101-40853

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  11. T½ el of ecopipam glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  12. T½ el of EBS-101-40853 glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  13. AUC0-4 for ecopipam

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  14. AUC0-4 for EBS-101-40853

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  15. AUC0-4 for ecopipam glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  16. AUC0-4 for EBS 101-40853 glucuronide

    Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis

    Time frame: Up to Day 21

  17. Minimum Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score

    Score from 0-5 where 0 is no response and 5 is responds readily. MOAA/S measures will be recorded at the indicated timepoints

    Time frame: Up to Day 21

  18. AUEC for Visual Analogue Scale (VAS)

    Score from 0 - 100 where 0 is not sedated and 100 is very sedated. VAS measures will be recorded at the indicated timepoints.

    Time frame: Up to Day 21

  19. Maximum sedation for Visual Analogue Scale (VAS)

    Score from 0 - 100 where 0 is not sedated and 100 is very sedated. VAS measures will be recorded at the indicated timepoints.

    Time frame: Up to Day 21

  20. AUEC for Reaction Time Index (RTI) score

    Reaction time for subject to release the response button after presentation of target stimulus.

    Time frame: Up to Day 21

  21. Maximum sedation for Reaction Time Index (RTI) score

    Reaction time for subject to release the response button after presentation of target stimulus.

    Time frame: Up to Day 21

  22. Safety and tolerability as demonstrated by AEs with itraconazole

    Subjects will be continually monitored for adverse events

    Time frame: Up to Day 30

  23. Safety and tolerability as demonstrated by AEs without itraconazole

    Subjects will be continually monitored for adverse events

    Time frame: Up to Day 30

  24. Safety and tolerability as demonstrated by AEs with rifampicin

    Subjects will be continually monitored for adverse events

    Time frame: Up to Day 30

  25. Safety and tolerability as demonstrated by AEs without rifampicin

    Subjects will be continually monitored for adverse events

    Time frame: Up to Day 30

  26. Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) with itraconazole (mmHG)

    Blood pressure will be assessed as part of vital signs

    Time frame: Up to Day 21

  27. Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) without itraconazole(mmHG)

    Blood pressure will be assessed as part of vital signs

    Time frame: Up to Day 21

  28. Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) with rifampicin(mmHG)

    Blood pressure will be assessed as part of vital signs

    Time frame: Up to Day 21

  29. Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) without rifampicin(mmHG)

    Blood pressure will be assessed as part of vital signs

    Time frame: Up to Day 21

  30. Heart rate with itraconazole (beats/minute)

    Heart rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  31. Heart rate without itraconazole (beats/minute)

    Heart rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  32. Heart rate with rifampicin (beats/minute)

    Heart rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  33. Heart rate without rifampicin (beats/minute)

    Heart rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  34. Respiratory rate pressure with itraconazole (breaths/minute)

    Respiratory rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  35. Respiratory rate without itraconazole (breaths/minute)

    Respiratory rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  36. Respiratory rate with rifampicin (breaths/minute)

    Respiratory rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  37. Respiratory rate without rifampicin (breaths/minute)

    Respiratory rate will be assessed as part of vital signs

    Time frame: Up to Day 21

  38. Oral temperature with itraconazole (degrees Celsius)

    Temperature will be assessed as part of vital signs

    Time frame: Up to Day 21

  39. Oral temperature without itraconazole (degrees Celsius)

    Temperature will be assessed as part of vital signs

    Time frame: Up to Day 21

  40. Oral temperature with rifampicin (degrees Celsius)

    Temperature will be assessed as part of vital signs

    Time frame: Up to Day 21

  41. Oral temperature without rifampicin (degrees Celsius)

    Temperature will be assessed as part of vital signs

    Time frame: Up to Day 21

  42. Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) with itraconazole (Milliseconds)

    Twelve-lead ECGs will be obtained at the indicated timepoints

    Time frame: Up to Day 21

  43. Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) without itraconazole (Milliseconds)

    Twelve-lead ECGs will be obtained at the indicated timepoints

    Time frame: Up to Day 21

  44. Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) with rifampicin (Milliseconds)

    Twelve-lead ECGs will be obtained at the indicated timepoints

    Time frame: Up to Day 21

  45. Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) without rifampicin (Milliseconds)

    Twelve-lead ECGs will be obtained at the indicated timepoints

    Time frame: Up to Day 21

  46. Safety and tolerability as demonstrated by the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS to be administered at the indicated timepoints

    Time frame: Up to Day 21

  47. Values of white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelets (1000/mm3)

    Blood samples will be collected for the assessment of hematology parameters

    Time frame: Up to Day 21

  48. Value of hematocrit (percent)

    Blood samples will be collected for the assessment of hematology parameters

    Time frame: Up to Day 21

  49. Value of hemoglobin (g/dL)

    Blood samples will be collected for the assessment of hematology parameters

    Time frame: Up to Day 21

  50. Red blood cell (RBC) count (M/mm3)

    Blood samples will be collected for the assessment of hematology parameters

    Time frame: Up to Day 21

  51. Values of sodium, potassium, chloride (mmol/L)

    Blood samples will be collected for the assessment of clinical chemistry parameters

    Time frame: Up to Day 21

  52. Values of urea, phosphorus, calcium, glucose, and total, direct and indirect bilirubin (mg/dL)

    Blood samples will be collected for the assessment of clinical chemistry parameters

    Time frame: Up to Day 21

  53. Values of albumin and total protein (g/dL)

    Blood samples will be collected for the assessment of clinical chemistry parameters

    Time frame: Up to Day 21

  54. Values of alanine aminotransferase (ALT), aspartate aminotransferase (AST),alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), creatininephosphokinase (CPK), and creatinine (U/L)

    Blood samples will be collected for the assessment of clinical chemistry parameters

    Time frame: Up to Day 21

  55. Values of urine specific gravity

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  56. Values of urine pH

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  57. Values of urine glucose

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  58. Values of urine protein

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  59. Values of urine blood

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  60. Values of urine ketones

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  61. Values of urine bilirubin and nitrite

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  62. Values of urobilinogen

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

  63. Values of urine leukocyte esterase by dipstick

    Urine samples will be collected for the assessment of urine parameters

    Time frame: Up to Day 21

07

Study locations

1 site
  • Syneos Health Clinic Inc.
    Québec, Quebec G1P 0A2, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in May 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 8, 2024
StartActual
Jan 18, 2024
Primary completionActual
May 14, 2024
CompletionActual
May 22, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06194864
Lead sponsor
Emalex Biosciences Inc.
Collaborators
Syneos Health, Cambridge Cognition Ltd
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Jan 18, 2024
Primary completion
May 14, 2024
Completion
May 22, 2024
Last update
Sep 19, 2024

Study contacts

Rick Munschauer, MSc, MD, FAAN
study director · Emalex Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Rifampin · Ecopipam

Start the discussion